featured
-
Getting to the Root of Huntington's Disease: A Plant-Based Approach
Researchers used plants to study how to stop the Huntington’s disease protein from forming toxic clumps
-
Could halting CAG expansions be a new treatment for HD?
The gene MSH3 is getting a lot of attention in HD research lately. New findings suggest MSH3 lowering could halt CAG repeat expansions, offering a new therapeutic avenue.
-
Tipping the balance; new insights into HD genetic modifiers
A new study from researchers at Thomas Jefferson University delves into the details of how genetic modifiers of Huntington’s disease work.
-
Drug to treat movement symptoms of HD approved by FDA
The FDA has approved valbenazine, also known as INGREZZA, as a treatment for the movement symptoms of Huntington’s disease
-
Youthful competitors: young brain cells oust the old
Replacing cells with HD in the brain could be an effective treatment strategy. Recent work shows that glia injected into mouse brains take over and oust the older cells, but for a surprising reason – because of age, not HD!
-
Huntington’s disease therapeutics conference 2023 – Day 3
Check out research updates from Day 3 of the 2022 HD Therapeutics Conference #HDTC2023
-
Huntington’s disease therapeutics conference 2023 – Day 2
Check out research updates from Day 2 of the 2022 HD Therapeutics Conference #HDTC2023
-
Huntington’s disease therapeutics conference 2023 – Day 1
Check out research updates from Day 1 of the 2022 HD Therapeutics Conference #HDTC2023
-
PROOF-HD study of pridopidine ends with negative result
The phase 3 trial missed its primary endpoint of slowing loss of function in Huntington’s disease
-
Astrocytes: The new star in HD research?
A new article summarizes what the Huntington's disease field has found about a type of brain cell called an astrocyte. These star-shaped cells help keep brain cells healthy and could be leveraged for developing new HD therapeutics.